ArticleAnnals of nuclear medicine2026
Prognostic value of 18F-FDG PET/CT derived metabolic parameters in pediatric osteosarcoma.
Article in Annals of nuclear medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate whether metabolic and volumetric 18F-FDG PET parameters are associated with histopathological response, metastatic disease at diagnosis, overall survival (OS), and progression-free survival (PFS) in pediatric osteosarcoma (OST) patients. Additionally, to compare absolute and relative threshold methods for metabolic tumor volume (MTV) calculation.
methodsThis single-center retrospective study included 26 pediatric OST patients who underwent 18F-FDG PET/CT at diagnosis and, when available, after neoadjuvant chemotherapy. SUVmax, SUVpeak, MTV, total lesion glycolysis (TLG) and anatomic tumor volume of the primary tumor, along with whole-body MTV (wb-MTV) and whole-body TLG encompassing all FDG-avid metastatic lesions, were measured and their percentage changes (∆) between PET scans were calculated. MTV and TLG were calculated using absolute (SUV 2.0) and relative (40% of tumor SUVmax) threshold methods.
resultsBaseline 18F-FDG PET parameters did not predict histopathological response. But, we found that ΔSUVmax, ΔMTV (2.0), ΔTLG (2.0), and ΔTLG (40%) were associated with histopathological response (p = 0.029). Although not statistically significant, patients with metastases had higher baseline SUVmax, SUVpeak, MTV (2.0), and TLG (2.0) values. Anatomic tumor volume did not differ between the metastatic and localized groups. Patients with wb-MTV (40%) > 137.5 had a significantly higher mortality risk (HR = 4.27, p = 0.017). Kaplan-Meier analysis revealed that patients with primary tumors exhibiting SUVmax > 5.56 and SUVpeak > 4.57 had significantly lower estimated 5-year OS rates (p = 0.036 and 0.029), even after excluding patients with metastasis at diagnosis.
conclusionsΔSUVmax, ΔMTV (2.0), ΔTLG (2.0), and ΔTLG (40%) were found to be associated with histopathologic response, suggesting that these changes may serve as predictors of histopathologic outcome. MTV (2.0) may be a more reliable indicator of tumor aggressiveness than anatomic tumor volume, as it tended to be higher in the metastatic group. Our finding suggests that using absolute threshold may better reflect tumor burden in primary lesions with high metabolic activity, whereas relative threshold may be more suitable for evaluating total tumor burden, including low 18F-FDG uptake metastases. Inferior survival outcome is associated with elevated baseline SUVmax and SUVpeak values persisted even when patients with metastatic disease were excluded, suggesting their potential prognostic value.
Indexed as
Identifiers
41212372What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.